HER2Negative Metastatic Breast Cancer - Pipeline Insight, 2024

HER2Negative Metastatic Breast Cancer - Pipeline Insight, 2024

DelveInsight’s, “Her2Negative-Metastatic-Breast-Cancer- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Her2Negative-Metastatic-Breast-Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Her2Negative-Metastatic-Breast-Cancer: Understanding

Her2Negative-Metastatic-Breast-Cancer: Overview

Breast cancer is the world’s most common disease in women, and is also a major factor that leads to death. It is reported that 5% of patients with breast cancer have distant metastasis at a diagnosis, and 30% of patients with early cancer subsequently experience the distant metastasis. Metastatic breast cancer cannot be completely cured; however, significant improvement in the survival period was observed consistent with the emergence of novel therapy. The purpose of the treatment for metastatic breast cancer is to prolong the survival period and improve the cancer patients’ quality of life (QOL) by managing cancer-related symptoms. To that end, not the same strategy for all patients but individual approach for each patient should be used. When a breast cancer is HER2-negative, it means that the cancerous cells do not contain high levels of the protein HER2. There are many treatment options available for this type of breast cancer, but the outlook can vary. “HER2” stands for human epidermal growth factor receptor 2. It may refer to the HER2 gene or to the protein HER2, which the gene makes.HER2 proteins are receptors that sit on the surface of breast cells. They usually help control the growth and repair of healthy breast tissue. Most studies divide HER2-negative breast cancer into two types. Based on the presence or absence of hormone receptors on the surface of cancer cells: hormone receptor-positive (HR-positive) breast cancer, triple-negative breast cancer. When person have HER2-negative advanced (metastatic) breast cancer, treatment usually focuses on managing the disease, not curing the cancer. The goal is to help a person live longer and have a better quality of life. This type of cancer is most often treated with systemic therapy. These drugs go into the bloodstream to send treatment to cells and organs throughout the body. Hormonal therapy is often the first treatment doctor’s use for women with HER2-negative advanced breast cancer that's ""hormone receptor positive."" Some 50%-70% of breast cancers are hormone receptor positive. That means that the hormones, like estrogen or progesterone, help the cancer grow. Hormonal or endocrine therapies help to block this process. Some drugs lower your levels of estrogen. Others stop estrogen from connecting to cancer cells so they can’t multiply. Hormonal therapies have a lower risk of serious side effects than chemotherapy. Many different chemotherapy drugs are used, either alone or in combination, to treat HER2-negative breast cancer. Targeted therapies block certain proteins or molecules that drive the growth and spread of cancer cells. Those molecules are the ""targets"" of the drugs. There’s a lot of research into targeted therapies for cancer. These drugs are also called precision medicine. Once diagnosed with HER2-negative advanced breast cancer, patient may also consider starting palliative care. Palliative therapies treat pain, anxiety, and other issues that can come along with cancer.

""Her2Negative-Metastatic-Breast-Cancer- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Her2Negative-Metastatic-Breast-Cancer pipeline landscape is provided which includes the disease overview and Her2Negative-Metastatic-Breast-Cancer treatment guidelines. The assessment part of the report embraces, in depth Her2Negative-Metastatic-Breast-Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Her2Negative-Metastatic-Breast-Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Her2Negative-Metastatic-Breast-Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Her2Negative-Metastatic-Breast-Cancer.

Her2Negative-Metastatic-Breast-Cancer Emerging Drugs Chapters

This segment of the Her2Negative-Metastatic-Breast-Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Her2Negative-Metastatic-Breast-Cancer Emerging Drugs

• Pamiparib: BeiGene

Pamiparib is a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2 enzymes that is being evaluated as a potential monotherapy and in combinations for the treatment of various solid tumors. It is believed that pamiparib has the potential to be differentiated from other PARP inhibitors because of its brain penetration, greater selectivity, strong DNA-trapping activity, and good oral bioavailability demonstrated in preclinical models. . Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Her2Negative-Metastatic-Breast-Cancers.

• Onapristone: Context Therapeutics

ONA-XR is an investigational medicine that prevents progesterone signaling by blocking the interaction between progesterone and its binding partner, progesterone receptor. Onapristone is the only known full PR antagonist. Currently, there are no approved therapies that selectively target progesterone receptor positive (PR+) cancers. Preclinical and clinical data suggest that onapristone extended release (ONA-XR) has anticancer activity by inhibiting PR binding to chromatin, down regulating cancer stem cell mobilization and blocking immune evasion. ONA-XR is currently being evaluated in four Phase 2 trials and two Phase 0 biomarker pharmacodynamic trials in women with primary or metastatic breast, ovarian, and endometrial cancers. . Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Her2Negative-Metastatic-Breast-Cancers.

Further product details are provided in the report……..

Her2Negative-Metastatic-Breast-Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Her2Negative-Metastatic-Breast-Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Her2Negative-Metastatic-Breast-Cancer

There are approx. 50+ key companies which are developing the therapies for Her2Negative-Metastatic-Breast-Cancer. The companies which have their Her2Negative-Metastatic-Breast-Cancer drug candidates in the most advanced stage, i.e. phase II include, BeiGene.

• Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Her2Negative-Metastatic-Breast-Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Her2Negative-Metastatic-Breast-Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Her2Negative-Metastatic-Breast-Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Her2Negative-Metastatic-Breast-Cancer drugs.

Her2Negative-Metastatic-Breast-Cancer Report Insights

• Her2Negative-Metastatic-Breast-Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Her2Negative-Metastatic-Breast-Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Her2Negative-Metastatic-Breast-Cancer drugs?
• How many Her2Negative-Metastatic-Breast-Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Her2Negative-Metastatic-Breast-Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Her2Negative-Metastatic-Breast-Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Her2Negative-Metastatic-Breast-Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• BeiGene
• Context Therapeutics
• Astex Pharmaceuticals
• Eisai Inc.
• AstraZeneca
• Dantari, Inc.

Key Products

• Pamiparib
• Onapristone
• ASTX-727
• Durvalumab
• DAN-222